Drug – bio-affecting and body treating compositions – Immune response affecting drug
Reexamination Certificate
2005-10-25
2005-10-25
Wang, Andrew (Department: 1635)
Drug, bio-affecting and body treating compositions
Immune response affecting drug
C514S002600, C424S184100
Reexamination Certificate
active
06958361
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.
REFERENCES:
patent: 5215926 (1993-06-01), Etchells, III et al.
patent: 5240856 (1993-08-01), Goffe et al.
patent: 5668267 (1997-09-01), Watson et al.
patent: 5855889 (1999-01-01), Watson et al.
patent: 5891857 (1999-04-01), Holt et al.
patent: 5922836 (1999-07-01), Watson et al.
patent: 5968754 (1999-10-01), Watson et al.
patent: 5986170 (1999-11-01), Subjeck
patent: 6004756 (1999-12-01), Watson et al.
patent: WO 89/06280 (1989-07-01), None
patent: WO 91/16116 (1991-10-01), None
patent: WO 92/07243 (1992-04-01), None
patent: WO 96/29430 (1996-09-01), None
patent: WO 98/21331 (1998-05-01), None
patent: WO 98/33915 (1998-08-01), None
patent: WO 98/54963 (1998-12-01), None
patent: WO 99/09155 (1999-02-01), None
patent: WO 00/08210 (2000-02-01), None
patent: WO 00/43420 (2000-07-01), None
patent: WO 00/60076 (2000-10-01), None
patent: WO 00/73801 (2000-12-01), None
patent: WO 01/37779 (2001-05-01), None
patent: WO 01/47959 (2001-07-01), None
Doerks et al. (1998, Trends in Genetics 14:248-250).
Anderson et al. Electrophoresis 1997, vol. 18, pp. 533-537.
* A copy of this reference was previously forwarded to Applicants in U.S. Appl. No. 09/604,287.
Skolnick et al. (2000, Trends in Biotech. 18:34-39).
Bork (2000, Genome Research 10:398-400).
Thompson (2001), Medicinal Research Reviews. vol. 21, No. 5, pp. 412-449.
Gura (Science, 1997, vol. 278, pp. 1041-1042).
Hartwell et al. (Science, 1997, vol. 278, pp. 1064-1068).
GenBank Database, Accession No. AA219147, Feb. 7, 1997.
GenBank Database, Accession No. AI272025, Nov. 17, 1998.
GenBank Database, Accession No. AI687645, May 27, 1999.
GenBank Database, Accession No. AL049911, Oct. 22, 1999.
GenBank Database, Accession No. AQ280806, Nov. 22, 1998.
Geneseq (Derwent) Database, Accession No. AAV41453, Oct. 12, 1998.
Geneseq (Derwent) Database, Accession No. AAV90291, Feb. 15, 1999.
Chang and Shu, “Current status of adoptive immunotherapy of cancer,”Critical Reviews in Oncology/Hematology 22(3):213-228, Apr. 1996.
Cheever and Chen, “Therapy with cultured T cells: principles revisited,”Immunological Reviews, 157:177-194, 1997.
Cheever et al., “Potential uses of interleukin 2 in cancer therapy,”Immunobiol, 172:365-382, 1986.
Chen et al., “T-cells for tumor therapy can be obtained from antigen-loaded sponge implants,”Cancer Research 54(4):1065-1070, Feb. 15, 1994.
Cole et al., “Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigent,”Cancer Research, 55:748-752, Feb. 15, 1995.
Durrant L., “Cancer vaccines,”Anti-Cancer Drugs, 8:727-733, 1997.
Eshhar Z., “Tumor-specific T-bodies: toward clinical application,”Cancer Immunol Immnother, 45:131-136, 1997.
GenBank Accession No. AC069200, May 24, 2000.
GenBank Accession No. AF269087, Mar. 28, 2001.
GenBank Accession No. AAK27325, Mar. 28, 2001.
GenBank Accession No. AA864891, Feb. 20, 1998.
GenBank Accession No. AA398925, Apr. 25, 1997.
GenBank Accession No. AL359312, Dec. 7, 2001.
Geneseq Accession No. V84525 (Dec. 10, 1998).
Hwu et al., “In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes,”Cancer Research, 55:3369-3373, Aug. 1, 1995.
Jäger et al., “Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library,”Cancer Research 61(5):2055-2061, Mar. 1, 2001.
Porter-Jordan and Lippman, “Overview of the biologic markers of breast cancer,”Breast Cancer 8:(1):73-100, Feb. 1994.
Prilliman et al., “HLA-B15 peptide ligands are preferentially anchored at their c termini,”The Journal of Immunology 162(12):7277-7284, Jun. 15, 1999.
Sulston et al., “Toward a complete human genome sequence,”Genome Research 8(11):1097-1108, 1998.
Stratagene 1991 product catalog, Prime-It™ Random Labeling Kit, catalog No. 300387, p. 66.
Wei et al., “Protection against mammary tumor growth by vaccination with full-length, modified humanErbB-2DNA,”Int. J. Cancer, 81:748-754, 1999.
GenBank Accession No. AL157387, Feb. 18, 2000.
GenBank Accession No. AC036170, Apr. 9, 2000.
Houghton Raymond L.
Persing David H.
Sleath Paul R.
Corixa Corporation
Epps-Ford Janet L.
Wang Andrew
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3478052